D3 Bio

D3 Bio is a globally focused biotechnology company developing and registering innovative medicines in oncology and immunology. Rather than starting purely in the lab, D3 Bio first pinpoints the greatest unmet patient and market needs, then applies fit-for-purpose science to define its drug development path, building a portfolio of internal and in-licensed assets with backbone potential for multiple indications. Founded and led by oncologist George Chen, MD, a former senior executive at the NIH, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, BeiGene, and AstraZeneca, the company is backed by investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund. Its lead program, D3S-001, a KRAS G12C-selective inhibitor, has received FDA Breakthrough Therapy and Orphan Drug designations.